With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
The latest business developments from across Asia by Heather Hobbs
Sino-German Strategic Cooperation Creates a new Chapter for Pfeiffer Vacuum in China
Pfeiffer Vacuum has signed a strategic cooperation agreement with Lanzhou Institute of Physics (LIP) in Asslar, Germany. As one of the founders of the Chinese Vacuum Society, the Lanzhou Institute of Physics is a pioneer in vacuum technology in China. LIP is also one of the fi rst institutes in China which has been directly engaged in satellite and spacecraft development and is therefore a part of the China Academy of Space Technology (CAST) since 1968. Pfeiffer Vacuum and LIP will cooperate in research and development to create vacuum solutions for aerospace applications, vacuum metrology, vacuum calibration and other applications.
The strong cooperation between the two companies is in line with the common interests of both sides. Pfeiffer Vacuum is contributing with its extensive line of solutions, products and services ranging from vacuum pumps, measurement and analysis equipment to complex vacuum systems and its global sales and service network, while LIP is introducing its leading position in the China vacuum industry.
On 17 October 2017, the LIP-Pfeiffer Vacuum Joint Center for Vacuum Technology was established in Lanzhou, Gansu province. The centre will provide a platform for future projects and joint developments. As mentioned by LIP during the opening ceremony, it will connect ‘Made in China 2025’ and the German ‘Industry 4.0’ initiatives.
The LIP-Pfeiffer Vacuum Joint Center for Vacuum Technology unveiling ceremony in Lanzhou, Gansu Province, China.
The start of the cooperation between Pfeiffer Vacuum and the Lanzhou Institute of Physics is in conjunction with the 10th anniversary of Pfeiffer Vacuum in China. “We hope that with our experience and advanced technology we can provide leading vacuum solutions and fi rst-class service to create a bright future for our Chinese customers,” said Vic Chen, General Manager of Pfeiffer Vacuum (Shanghai) Co, Ltd.
44643pr@reply-direct.com
UK/Chinese Collaboration to Develop Innovative Technologies for Epigenetic Analysis Announced
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising potential for other companies to move into export markets.
Vetter Expands its Footprint in Asia Pacifi c Region
spot’ by the industry as it houses numerous prominent biopharmaceutical companies and service providers.
The ribbon cutting ceremony takes place for Vetter. Left to right: Mr Michael Vetter (Strategic Market Development, Vetter), Mr Park Yoon-bae (President, Incheon Business Information Technopark), Mr Cho, Dong-Am (Vice Mayor for Political & Economic Affairs, Incheon Metropolitan City), Mr Peter Soelkner (Managing Director, Vetter), Mrs Chervee Ho (Director Key Account Management Asia Pacifi c, Vetter) and Mr Oskar Gold (Senior Vice President Key Account Management and Marketing/Corporate Communications, Vetter).
Vetter, a global leaders in prefi lled drug-delivery systems, have announced the offi cial opening of a new branch offi ce in South Korea. The new offi ce in Songdo is located within the biologics cluster which is often referred to as a ‘sweet
Strengthening its global footprint in the Asia Pacifi c (APAC) region has been an ongoing goal for Vetter. The company established its APAC hub in Singapore in 2014, and subsequently formed a Japanese subsidiary by opening an offi ce in Tokyo in 2015. Although the pharmaceutical service provider had already been active in the South Korean market for years, the establishment of its own local branch offi ce underlines the company’s commitment to the Asia Pacifi c market, particularly South Korea. With the new footprint, Vetter will be better positioned to support its existing South Korean business as well as that of new local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.
“Today is yet another milestone for our company. This new offi ce will allow us to directly serve both local and global companies with South Korean market interests,” said Vetter Managing Director Peter Soelkner. “We are certain that our market presence and activities in this market will serve as an additional base and contribution for Vetter’s future global organic growth.”
44421pr@reply-direct.com
Eppendorf India Expands Chennai Training Facility Eppendorf India, a wholly owned subsidiary of Eppendorf
AG, have announced the extension of the training centre at its facility in Ambattur, Chennai. Eppendorf is committed to skill development and this measure further enhances the possibility of offering tailor made training programs for Biotechnology students, faculties and researchers.
The state of the art facility is equipped with the latest range of life science research products covering the 3 competence areas of liquid handling, sample handling and cell handling. The centre is also equipped with laboratories for cell cultivation and Bioprocess applications.
Thomas Bachmann, Chairman & CEO of the Eppendorf Group: “One of the cornerstones of our business strategy is to strengthen our global market position through targeted investments in both our sales structure and expansion of our training and service portfolio.
Dr Amy Beynon
Porvair Sciences are teaming up with Suzhou Tianlong Bio Technology Co Ltd, together with Swansea University and Xi’an Jiaotong University in a collaborative project entitled, ‘Automating and Stratifi cation of Epigenetics in Healthcare’ that is part of the Innovate UK/Jiangsu Industrial Challenge Programme.
The project will integrate Porvair’s innovative solid-state chromatin immunoprecipitation platform, Chromatrap® with Tianlong’s expertise in automated robotic technologies and diagnostic multiplex PCR kits to develop innovative technologies in epigenetic characterisation for patient stratifi cation in renowned precision medicine. Academics in cancer epigenetics from Swansea University and Xi’an Jiaotong University will support the project by providing insights and direction for the application in cancer research and drug development.
Dr Amy Beynon, Technical and Business Development Manager at Porvair Sciences said: “Developing new technologies to simplify and advance epigenetics research is the driving force here at Porvair. Combining Chromatrap with Tianlong’s expertise in diagnostic multiplex arrays, we will provide a streamlined workfl ow across both research and clinical applications. The ultimate collaborative goal is to provide innovative tools that improve diagnostic options for patients and informed novel stratifi ed therapeutics.”
Vancheeswaran Sankaranarayanan, Managing Director & CEO, Eppendorf India states: “During the decade- long presence of Eppendorf in India, we have extended signifi cant support to the life sciences and biotechnology industry in India. Our dominant market position in India demonstrates the superiority of our products and underscores the importance of our training and service workshops extended to the clients’ R&D scientists continuously. With continually increasing demand for our premium products and services in India, Eppendorf India will work to increase considerably our customer-focussed initiatives with our expanded training centre.
44443pr@reply-direct.com
The project will provide an excellent opportunity for Porvair Sciences and Tianlong to develop an automated ChIP assay that enables users to perform chromatin isolation straight through to multiplex PCR, completely hands-free. Researchers and diagnostic laboratories will be able to simultaneously analyse multiple epigenetic marks using less material and obtain better quantitative analyses. Diagnostic multiplex arrays are currently available for a number of cancer disease states, but application in breast and ovarian cancers is non-existent which greatly impacts the development of novel therapeutics.
Dr Lindsay Parkes a Senior Research Scientist at Porvair Sciences emphasised that “the opportunity to be the fi rst to provide fundamental technologies for precision medicine, starting with breast and ovarian cancer, we can begin to shed light on the underlying epigenetics processes in cancer biology and take the fi rst steps in developing therapeutics solutions for patients.”
44663pr@reply-direct.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
